证券代码：600535 证券简称：天士力 编号：临 2025-072 号 天士力医药集团股份有限公司 第九届董事会第 16 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 天士力医药集团股份有限公司（以下简称"公司"）第九届董事会第 16 次会 议通知于 2025 年 12 月 4 日以书面方式发出，会议于 2025 年 12 月 9 日以通讯方 式召开，会议应到董事 15 人，实到 15 人。会议符合《公司法》和《公司章程》 的有关规定，会议合法、有效。经与会人员逐项审议，通过了以下议案： 一、关于取消监事会并修订《公司章程》的议案 内容详见公司在上海证券交易所网站（www.sse.com.cn）发布的《关于取消 监事会并修订<公司章程>及修订、制定部分治理制度的公告》（公告编号：2025-074 号）。本议案尚需提交公司 2025 年第六次临时股东会审议。 表决情况为：有效表决票 15 票，其中：同意 15 票，反对 0 票，弃权 0 票。 二、关于修订及制定部分公司治理制度的议案 为进一步提升公司规 ...

Group 1 - The core point of the article is that Tian Shi Li (SH 600535) held its 16th meeting of the 9th Board of Directors on December 9, 2025, to review proposals regarding the revision and establishment of certain corporate governance systems [1] - For the year 2024, Tian Shi Li's revenue composition is as follows: Traditional Chinese medicine accounts for 70.89%, chemical preparations for 15.38%, pharmaceutical commerce for 10.53%, biological drugs for 2.25%, and chemical raw materials for 0.61% [1] - As of the report date, Tian Shi Li's market capitalization is 22.7 billion yuan [1] Group 2 - The article also highlights a significant issue in the pharmaceutical industry regarding the abuse of pregabalin, marking the first reported case of addiction in China, which raises concerns about the accessibility of prescription drugs without proper medical records [1]

天士力公告，公司董事会于2025年12月9日收到副总经理席凯的辞职报告。席凯因工作调整原因提请辞 去副总经理职务，辞任后将继续担任职工董事、党委副书记。席凯的辞职自报告送达董事会时生效，不 会影响公司正常生产经营。席凯未持有公司股票，不存在未履行的公开承诺。 ...

近日，天士力举办第三季度业绩说明会，据天士力总经理蔡金勇表示，目前公司正全面推进与华润三九 的首年融合工作，从"价值重塑"、"业务重塑"、"组织重塑"和"精神重塑"四个维度系统化升级管理体 系，实现强强联合的战略协同。 在运营管理方面，公司积极落实华润管理理念，加强财务、人力资源、EHSQ 及大监督体系的融合，开 展"焕新增效"等系列组织优化活动，优化运营管控模式，提升管理效率，为后续业务协同和战略落地奠 定了坚实基础；在战略规划方面，公司高效组织管理层与华润三九管理层进行多次战略融合研讨，通过 洞察行业变化趋势，并结合公司实际情况，启动了"十五五"战略规划的制订工作，力求为公司未来发展 指明方向，推动公司在创新求变新征程中实现高质量发展。 同时，公司加大与华润旗下商品以及华润医药商业和医药物流的协同，借助华润三九的品牌优势，提升 连锁药店的行业竞争力。 （上证路演） (编辑：杨燕 林辰)关键字： 医疗 在百日融合期内，公司与华润三九协同赋能，在营销领域整合线上线下渠道资源，创新医药零售新模 式。在营销领域积极与华润进行融合赋能，基于目前公司产品结构以及市场渠道特点，通过充分整合资 源、优势互补，达成米诺磷酸 ...

Core Viewpoint - The company, Tasly Pharmaceutical Group Co., Ltd., is set to hold a Q3 2025 earnings presentation on December 4, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The earnings presentation will take place on December 4, 2025, from 15:00 to 16:00 [2][6]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [2][6]. - The meeting will be conducted in an interactive online format, allowing for real-time engagement with investors [3][5]. Group 2: Investor Participation - Investors can submit questions for the presentation from November 27, 2025, to December 3, 2025, by visiting the Roadshow Center's website or via the company's email [2][7]. - The company will address commonly asked questions during the earnings presentation [3][7]. Group 3: Company Representatives - Key representatives from the company include Mr. Cai Jinyong (General Manager), Mr. Yu Jie (Board Secretary), and Ms. Wei Jie (Chief Financial Officer) [4].

证券代码：600535 证券简称：天士力 编号：临 2025-071 号 天士力医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2025 年 12 月 4 日（星期四）15:00-16:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.ssei nfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 27 日（星期四）至 2025 年 12 月 3 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stock@tasly.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 天士力医药集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 25 日发 布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第 三季度经营成果、财务状况，公司计划于 2025 年 ...

Core Insights - The introduction of the innovative biopharmaceutical Puyouke by Tianshili represents a significant breakthrough in thrombolytic therapy for acute ischemic stroke, particularly for elderly patients who face high bleeding risks during treatment [1][2] - Recent studies published in top medical journals indicate that patients treated with Puyouke experience lower rates of hemorrhagic complications compared to control groups, highlighting its unique advantages in stroke treatment [2] - The "Lung·New Life" stroke prevention project, supported by Tianshili, aims to enhance the quality and quantity of ischemic stroke treatments in line with national health strategies, focusing on training healthcare professionals and improving public awareness [3][4] Company Developments - Tianshili's Puyouke is positioned to balance effective thrombolysis with reduced bleeding risks, enhancing its market potential and expanding the company's product line in the neurology sector [2][4] - The company is actively involved in community outreach and education initiatives to improve stroke prevention and treatment awareness, particularly in underserved areas [6][5] - Tianshili's commitment to innovation and social responsibility is evident in its support for the "Lung·New Life" project, which aims to provide comprehensive stroke care and improve healthcare access [5][7] Industry Trends - The evolution of thrombolytic therapies has shifted towards safer and more effective treatments, with Puyouke exemplifying this trend through its unique molecular structure and mechanism of action [4] - The national health strategy emphasizes the need for increased access to intravenous thrombolysis treatments in medical institutions, aligning with Tianshili's initiatives [3] - The dual focus on clinical needs and technological innovation in the pharmaceutical industry is highlighted by Tianshili's approach, which serves as a model for sustainable development in China's healthcare sector [7]

Group 1 - A fruit store in Ningbo was fined 50,000 yuan for issuing 28 false invoices to Tian Shi Li Pharmaceutical Group Co., Ltd. and Tian Shi Li Di Yi Pharmaceutical Co., Ltd. [1][7] - The total amount of the false invoices was 66,800.04 yuan, which included both the price and tax [7]. - The tax authority confiscated illegal income of 6,206 yuan from the fruit store in addition to the fine [7][8]. Group 2 - Tian Shi Li Pharmaceutical Group Co., Ltd. is a publicly listed pharmaceutical company in A-shares, while Tian Shi Li Di Yi Pharmaceutical Co., Ltd. is its wholly-owned subsidiary [7]. - The case raises questions about the authenticity of transactions between the fruit store and the pharmaceutical companies, as the nature of their business dealings remains unclear [7].

Core Insights - Shenzhen has emerged as a key engine city in the Guangdong-Hong Kong-Macao Greater Bay Area, showcasing significant achievements in capital market development during the 14th Five-Year Plan period, with over 400 billion yuan in equity financing and a leading proportion of technology companies listed [1][2] Group 1: Capital Market Development - During the 14th Five-Year Plan, Shenzhen's capital market facilitated over 400 billion yuan in equity financing, supporting advanced manufacturing projects [2] - The proportion of companies listed on the Growth Enterprise Market and the Sci-Tech Innovation Board reached 50.24%, the highest among major cities in China [2] - Shenzhen's overall R&D investment intensity reached a global leading level, with listed companies' R&D expenditure totaling 210.33 billion yuan in 2024, a 91.35% increase from 2020 [2] Group 2: Market Performance - In the first three quarters of 2025, Shenzhen's listed companies achieved a total revenue of 5.2 trillion yuan and a net profit of 457.797 billion yuan, reflecting year-on-year growth of 7.36% and 3.98%, respectively [3] - Shenzhen's securities firms ranked first nationally in performance, with public and private fund management scales among the top three [3] Group 3: Investor Engagement and Protection - During the 14th Five-Year Plan, 1,486 listed companies in Shenzhen implemented cash dividends totaling nearly 990 billion yuan, significantly exceeding the equity financing amount [4] - The regulatory authorities maintained a "zero tolerance" approach to violations, enhancing investor confidence and market integrity [4][6] Group 4: Future Directions - The Shenzhen government aims to establish a globally influential industrial financial center, focusing on high-quality development in banking, securities, insurance, venture capital, and mergers and acquisitions [7][8] - The capital market will emphasize the development of new productive forces, guiding funds towards high-tech and high-quality sectors to support industrial transformation and innovation [8]

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. has received approval from the National Medical Products Administration for its innovative biological drug "Recombinant Human Urokinase (Puyouke)" for the treatment of acute ischemic stroke (AIS), addressing the specificity issues of traditional thrombolytic drugs in the stroke field [4][9]. Group 1: Product Approval and Market Impact - The new indication approval for Puyouke follows its previous approval for treating acute ST-segment elevation myocardial infarction, enhancing its role in stroke treatment [4]. - Puyouke targets occlusive thrombus specifically, activating plasminogen at the site of occlusion, which reduces systemic activation of the fibrinolytic system, thus lowering the risk of bleeding and improving patient outcomes [7][9]. Group 2: Challenges in Stroke Treatment - China faces significant challenges in the prevention and treatment of acute ischemic stroke, with approximately 3.3 million new cases annually, making it the leading cause of death and disability among adults [6]. - Public awareness of stroke symptoms and emergency response is low, with 67%-75% of patients missing the thrombolysis window due to delayed treatment [6]. - The rate of intravenous thrombolysis is only about 10%, and endovascular treatment is less than 1%, indicating a substantial gap compared to developed countries [6]. Group 3: Innovation and Production Challenges - The development of Puyouke required overcoming multiple technical barriers, including the stability and yield of the active ingredient, recombinant human urokinase [8]. - Tasly has established a comprehensive quality control system and stable production capacity, addressing the high barriers to commercial production of unstable enzyme products [8]. Group 4: Public Health Initiatives - The "Stroke Prevention and Treatment Capacity Enhancement and Health Promotion" project, initiated by the Chinese Stroke Association and supported by Tasly, aims to improve public awareness and enhance grassroots medical capabilities in stroke prevention and treatment [10][11]. - The project focuses on educating the public about stroke prevention and early treatment, as well as improving the diagnostic and treatment skills of primary care physicians [11].